Caspase cleaved presenilin-1 is part of active γ-secretase complexes

Victor Babes National Institute of Pathology, București, Bucureşti, Romania
Journal of Neurochemistry (Impact Factor: 4.28). 05/2006; 97(2):356-64. DOI: 10.1111/j.1471-4159.2006.03735.x
Source: PubMed


gamma-Secretase is a key enzyme involved in the processing of the beta-amyloid precursor protein into amyloid beta-peptides (Abeta). Abeta accumulates and forms plaques in Alzheimer's disease (AD) brains. A progressive neurodegeneration and cognitive decline occurs during the course of the disease, and Abeta is believed to be central for the molecular pathogenesis of AD. Apoptosis has been implicated as one of the mechanisms behind the neuronal cell loss seen in AD. We have studied preservation and activity of the gamma-secretase complex during apoptosis in neuroblastoma cells (SH-SY5Y) exposed to staurosporine (STS). We report that the known components (presenilin, Nicastrin, Aph-1 and Pen-2) interact and form active gamma-secretase complexes in apoptotic cells. In addition, the fragments corresponding to the PS1 N-terminal fragment and the caspase-cleaved PS1 C-terminal fragment (PS1-caspCTF) were found to form active gamma-secretase complexes when co-expressed in presenilin (PS) knockout cells. Interestingly, PS1-caspCTF replaced the normal PS1 C-terminal fragment and was co-immunoprecipitated with the gamma-secretase complex in SH-SY5Y cells exposed to STS. In addition, Abeta was detected in medium from apoptotic HEK APP(swe) cells. Together, the data show that gamma-secretase complexes containing PS1-caspCTF are active, and suggest that this proteolytic activity is also important in dying cells and may affect the progression of AD.

Download full-text


Available from: Bogdan O Popescu, Sep 09, 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: Secretases releasing fibril-forming fragments from Amyloid Precursor Protein (APP) that accumulate in extracellular deposits in Alzheimer's disease (AD) and parallel cognitive dysfunction, are described according to their historical discovery. These focus on metalloproteases that link to normal turnover (α-, ADAMs), a new family of Asp proteases (β-, BACE) for release of an intermediate for final cleavage by γ- to release amyloid β-peptide (Aβx). While α- and β-secretases are available in purified forms for rational synthesis of inhibitors, γ- exists only as a partially purified tetrameric complex (γ-SC) containing Presenilin, Nicastrin, Aph-1 and Pen-2 as obligatory components. Wide specificity of secretases precludes design of clinical agents to specifically target APP fragmentation. γ-SC cleavage of membrane-bound proteins points to important roles for Regulated Intramembrane Proteolysis (RIP) for both protein turnover and release of modulators of diverse signaling pathways. The review considers controversies regarding APP processing in sporadic AD (SAD), and the role of mutations for APP or Presenilin to exacerbate fibrillogenesis in familial AD (FAD). Progress in characterization of secretases provides a new basis for novel AD therapies and insights in general mechanisms of cellular protein turnover.
    No preview · Chapter · Feb 2007
  • [Show abstract] [Hide abstract]
    ABSTRACT: Recent discoveries on neurosecretases and their trafficking to release fibril-forming neuropeptides or other products, are of interest to pathology, cell signaling and drug discovery. Nomenclature arose from the use of amyloid precursor protein (APP) as a prototypic type-1 substrate leading to the isolation of beta-secretase (BACE), multimeric complexes (gamma-secretase, gamma-SC) for intramembranal cleavage, and attributing a new function to well-characterized metalloproteases of the ADAM family (alpha-secretase) for normal APP turnover. While purified alpha/beta-secretases facilitate drug discovery, gamma-SC presents greater challenges for characterization and mechanisms of catalysis. The review comments on links between mutation or polymorphisms in relation to enzyme mechanisms and disease. The association between lipoprotein receptor LRP11 variants and sporadic Alzheimer's disease (SAD) offers scope to integrate components of pre- and post-Golgi membranes, or brain clathrin-coated vesicles within pathways for trafficking as targets for intervention. The presence of APP and metabolites in brain clathrin-coated vesicles as significant cargo with lipoproteins and adaptors focuses attention as targets for therapeutic intervention. This overview emphasizes the importance to develop new therapies targeting neurosecretases to treat a major neurological disorder that has vast economic and social implications.
    No preview · Article · Feb 2008 · Neurochemistry International
  • [Show abstract] [Hide abstract]
    ABSTRACT: Memantine, a clinically used N-methyl-D-aspartate (NMDA)-receptor antagonist, has been shown to prevent apoptotic neuronal damage connected with the over-activity of NMDA receptors. In the present study, we examined the effect of memantine on staurosporine-, salsolinol- and doxorubicin-induced apoptosis in the SH-SY5Y cell line which does not possess functional NMDA receptors. Electrophysiological recordings and toxicity studies showed no response to NMDA-evoked currents in this cell line, irrespective of the stage of its neuronal differentiation. Memantine (0.1-2 microM) attenuated staurosporine-induced apoptosis as evidenced by reversal of the changes in mitochondrial membrane potential (DeltaPsi(m)) and decreased caspase-3 activity, lactate dehydrogenase (LDH) release and DNA fragmentation. Wortmannin (10 nM) and LY 294002 (10 microM) (inhibitors of phosphatidylinositol-3-kinase, PI3-K) reversed the inhibitory effect of memantine on the staurosporine-induced LDH release, suggesting that the PI3-K/Akt prosurvival pathway is a possible target for antiapoptotic action of memantine. Memantine at low micromolar concentrations also attenuated salsolinol- and doxorubicin-induced LDH release and DNA fragmentation, but only in the case of salsolinol was this effect accompanied by a decrease in caspase-3 activity. The present data indicate that memantine attenuates the toxic effects of various proapoptotic agents and the cytoprotective effect of memantine does not seem to be connected with its action on NMDA receptor but rather with its influence on intracellular pathways engaged in cellular survival/apoptotic processes.
    No preview · Article · Mar 2008 · Neurochemistry International
Show more